FDA sees bowel risk in early Glaxo vaccine data
WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.
Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.
"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.
Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.
Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.
The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.
(Reporting by Lisa Richwine; Editing by Maureen Bavdek)
- Tweet this
- Share this
- Digg this
- Google launches $105 Android One; eyes low-price smartphone boom
- Apple iPhone 6 pre-orders hit record 4 million on first day |
- LAPD investigates complaint from detained 'Django' actress
- Iran says it rebuffed US invitation to join anti-Islamic State coalition
- Alibaba to boost IPO size on "overwhelming" demand - sources
Liberia's President Ellen Johnson Sirleaf has sacked 10 senior officials because they failed to heed a warning to return from overseas travel to help the government's fight against an Ebola epidemic that has killed at least 1,100 Liberians. Full Article